Chemotherapy News and Research

Latest Chemotherapy News and Research

Radioactive gold nanoparticle treatment safe and effective in dogs with prostate cancer

Currently, large doses of chemotherapy are required when treating certain forms of cancer, resulting in toxic side effects. The chemicals enter the body and work to destroy or shrink the tumor, but also harm vital organs and drastically affect bodily functions. Now, scientists at the University of Missouri have proven that a new form of prostate cancer treatment that uses radioactive gold nanoparticles, and was developed at MU, is safe to use in dogs.

16 Oct 2012

Researcher uncovers mechanisms involved in prognosis of acute myeloid leukemia

When patients suffering from Acute Myeloid Leukemia (AML) express high levels of the gene, MN1, an already aggressive leukemia is accelerated and shortens survival time. While that's a known fact, the mechanisms involved aren't well understood which is why a Wake Forest Baptist Medical Center researcher decided to take a closer look.

16 Oct 2012

First Edition: October 15, 2012

Today's headlines include the latest developments and polling news from the presidential campaign trail as well as details about how Medicare and other health issues are shaping up in House and Senate races.

15 Oct 2012

Few physicians recommend active surveillance for low-risk prostate cancer

Few physicians recommend active surveillance for low-risk prostate cancer rather than pursuing surgery or radiation, according to a Mayo Clinic study being presented at the North Central Section of the American Urological Association's annual meeting Oct. 10-13 in Chicago.

15 Oct 2012

AXA PPP healthcare introduces new Facebook app for cancer patients

AXA PPP healthcare has launched a new Facebook application - little big things - for people affected by cancer to share inspirational tips and practical information on coping with the disease and its treatment.

15 Oct 2012

AAPS recognizes top scientists in pharmaceutical sciences

During the Opening Session of the 2012 American Association of Pharmaceutical Scientists (AAPS) Annual Meeting and Exposition, AAPS President David Y. Mitchell, Ph.D., presented the following ground-breaking researchers with awards commemorating their contributions to the pharmaceutical sciences:

15 Oct 2012

Celgene receives FDA approval for ABRAXANE to treat non-small cell lung cancer

Celgene Corporation today announced the U.S. Food and Drug Administration (FDA) has approved ABRAXANE (paclitaxel protein-bound particles for injectable suspension) (albumin-bound) for the first-line treatment of locally advanced or metastatic non-small cell lung cancer, in combination with carboplatin, in patients who are not candidates for curative surgery or radiation therapy.

15 Oct 2012

BC Cancer Agency second prestigious Vancouver institution to install MILabs Molecular Imaging System

MILabs is pleased to announce that the BC Cancer Agency, located in Vancouver, British Columbia will install a MILabs U‐SPECT/CT system to expand their current molecular oncology imaging and research capabilities. The U‐SPECT/CT is able to deliver high resolution, sensitivity and scanning speed contributing to outstanding quantification results and the ability to detect heterogeneous molecular processes in tumors.

12 Oct 2012

Lenalidomide worsens survival, adverse events in prostate cancer

A combination of lenalidomide plus docetaxel and prednisone treatment in patients with chemotherapy-naive prostate cancer leads to worse overall survival rates and increased toxicity compared with placebo, show study results.

12 Oct 2012

Novel method can determine how ready acute myeloid leukemia cells are to die

Researchers at Dana-Farber Cancer Institute have developed a novel method for determining how ready acute myeloid leukemia (AML) cells are to die, a discovery that may help cancer specialists to choose treatments option more effectively for their patients who have AML.

12 Oct 2012

Bidirectional communication between breast cancer cells and nearby MSCs cause metastasis

In recent years investigators have discovered that breast tumors are influenced by more than just the cancer cells within them. A variety of noncancerous cells, which in many cases constitute the majority of the tumor mass, form what is known as the "tumor microenvironment."

12 Oct 2012

T cells become more responsive in cancer survivors after exercise

Researchers may soon be able to add yet another item to the list of exercise's well-documented health benefits: A preliminary study suggests that when cancer survivors exercise for several weeks after they finish chemotherapy, their immune systems remodel themselves to become more effective, potentially fending off future incidences of cancer.

12 Oct 2012

UCI neuro-oncologist to lead DCVax Phase II trial in glioblastoma multiforme

UC Irvine doctors are enrolling patients with the deadly brain tumor glioblastoma multiforme in a clinical trial of a vaccine that may prevent the cancer's return or spread after surgery.

11 Oct 2012

Fibulin-3 protein may help identify mesothelioma in early stages

Researchers at NYU School of Medicine have discovered the protein product of a little-known gene may one day prove useful in identifying and monitoring the development of mesothelioma in early stages, when aggressive treatment can have an impact on the progression of disease and patient prognosis.

11 Oct 2012

NewLink Genetics to launch algenpantucel-L Phase 3 study in pancreatic cancer

NewLink Genetics Corporation announces launching of an open-label, randomized, multi-institutional Phase 3 study in patients with borderline resectable or locally advanced unresectable pancreatic cancer.

10 Oct 2012

PARP-1 plays a major role in controlling AR function in prostate cancer patients

A newly discovered function of PARP-1 could be the key to more effective therapeutics to treat advanced prostate cancer patients, a recent preclinical study published in Cancer Discovery by Jefferson's Kimmel Cancer Center researchers suggests.

10 Oct 2012

Chemotherapy plus immunotherapy can enhance anti-tumor effects in patients with advanced cancer

Researchers at Moffitt Cancer Center and colleagues at the University of South Florida and Tianjin Medical University Cancer Institute and Hospital in China have discovered that combining chemotherapy drugs and immunotherapy cancer vaccines results in an enhanced anti-tumor effect.

10 Oct 2012

Johns Hopkins joins API’s Actimab-A Phase I/II trial in acute myeloid leukemia

Actinium Pharmaceuticals, Inc. (API), a biopharmaceutical company that develops innovative targeted payload immunotherapeutics, announced that Johns Hopkins University School of Medicine in Baltimore, MD has joined the Company's ongoing Phase I/II trial in newly diagnosed elderly patients with acute myeloid leukemia (AML).

9 Oct 2012

HPV status predicts oropharyngeal cancer irradiation response

Human papillomavirus-positive head and neck cancer is more sensitive to the initial effects of radiation therapy than HPV-negative head and neck cancer, suggest study findings.

8 Oct 2012

NCI awards Cellerant SBIR contract to develop Megakaryocyte Progenitor Cell therapy for thrombocytopenia

Cellerant Therapeutics Inc., a biotechnology company developing novel hematopoietic stem cell-based cellular and antibody therapies for blood disorders and cancer, announced today that it has been awarded a Small Business Innovation Research (SBIR) Phase 1 contract and a Phase 2 option from the National Cancer Institute (NCI) valued up to $1,683,503.

8 Oct 2012